(Q37818151)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Clinical implications of pharmacogenetic variation on the effects of statins (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Simran Maggo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

David W J Clark

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

1 reference

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1-19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11584380-000000000-00000

17 January 2020

exact match

0 references

cites work

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect

1 reference

https://api.crossref.org/works/10.2165%2F11584380-000000000-00000

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584380-000000000-00000

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584380-000000000-00000

Biochemical functions of coenzyme Q10

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584380-000000000-00000

Effect of apolipoprotein E genotype and saturated fat intake on plasma lipids and myocardial infarction in the Central Valley of Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584380-000000000-00000

Assessing the cost-effectiveness of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584380-000000000-00000

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

12 December 2020

The APOE locus and the pharmacogenetics of lipid response

1 reference

12 December 2020

The genetic determinants of the CYP3A5 polymorphism

1 reference

12 December 2020

Best-selling human medicines 2002-2004.

1 reference

12 December 2020

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

1 reference

12 December 2020

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

1 reference

12 December 2020

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

1 reference

12 December 2020

The failure of torcetrapib: was it the molecule or the mechanism?

1 reference

12 December 2020

Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

1 reference

12 December 2020

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

1 reference

12 December 2020

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

1 reference

12 December 2020

Use of cholesterol-lowering medications in the United States from 1991 to 1997.

1 reference

12 December 2020

The human ATP-binding cassette (ABC) transporter superfamily.

1 reference

12 December 2020

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

1 reference

12 December 2020

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia

1 reference

12 December 2020

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

1 reference

12 December 2020

Pharmacogenetic study of statin therapy and cholesterol reduction

1 reference

12 December 2020

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

1 reference

12 December 2020

The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity

1 reference

12 December 2020

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

1 reference

12 December 2020

Statin safety: an appraisal from the adverse event reporting system

1 reference

12 December 2020

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

1 reference

12 December 2020

CoQ10 deficiency diseases in adults

1 reference

12 December 2020

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

1 reference

12 December 2020

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

1 reference

12 December 2020

CETP inhibitors to increase HDL cholesterol levels

1 reference

12 December 2020

A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study

1 reference

12 December 2020

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

1 reference

12 December 2020

Pharmacogenomics of cholesterol-lowering therapy

1 reference

12 December 2020

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

1 reference

12 December 2020

1 reference

12 December 2020

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

1 reference

12 December 2020

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

1 reference

12 December 2020

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

12 December 2020

Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio

1 reference

12 December 2020

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

1 reference

12 December 2020

Pharmacogenomics of statin responsiveness

1 reference

12 December 2020

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

1 reference

12 December 2020

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

1 reference

12 December 2020

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

1 reference

12 December 2020

Regulation of fatty acid synthesis by farnesyl pyrophosphate

1 reference

12 December 2020

Clinical outcomes in statin treatment trials: a meta-analysis

1 reference

12 December 2020

Pharmacogenomics of the OATP and OAT families

1 reference

12 December 2020

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

1 reference

12 December 2020

Linking pharmacovigilance with pharmacogenetics

1 reference

12 December 2020

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

12 December 2020

Oversight of US genetic testing laboratories

1 reference

12 December 2020

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

1 reference

12 December 2020

Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.

1 reference

12 December 2020

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

1 reference

12 December 2020

A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

1 reference

12 December 2020

Molecular mechanisms of muscle atrophy

1 reference

12 December 2020

Statin safety: a systematic review

1 reference

12 December 2020

CYP2D6*4 polymorphism is associated with statin-induced muscle effects

1 reference

12 December 2020

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

1 reference

12 December 2020

Statin safety: lessons from new drug applications for marketed statins.

1 reference

12 December 2020

Safety considerations for statins

1 reference

12 December 2020

A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy

1 reference

12 December 2020

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

1 reference

12 December 2020

Pharmacogenetics and adverse drug reactions

1 reference

12 December 2020

Impact of OATP transporters on pharmacokinetics

1 reference

12 December 2020

P-glycoprotein: from genomics to mechanism.

1 reference

12 December 2020

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

1 reference

12 December 2020

Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants

1 reference

12 December 2020

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

1 reference

12 December 2020

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

1 reference

12 December 2020

Pharmacogenetics: the outlook for genetic testing in statin therapy

1 reference

12 December 2020

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

1 reference

12 December 2020

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

1 reference

12 December 2020

Update on statins: 2003.

1 reference

12 December 2020

Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

1 reference

12 December 2020

Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.

1 reference

12 December 2020

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

1 reference

12 December 2020

Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy

1 reference

12 December 2020

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

1 reference

12 December 2020

Genetic determinants of statin intolerance

1 reference

12 December 2020

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

1 reference

12 December 2020

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

1 reference

12 December 2020

Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland

1 reference

12 December 2020

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

1 reference

12 December 2020

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy

1 reference

12 December 2020

Genetic polymorphisms of the human MDR1 drug transporter

1 reference

12 December 2020

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.

1 reference

12 December 2020

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

1 reference

12 December 2020

Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment

1 reference

12 December 2020

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

1 reference

12 December 2020

Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy

1 reference

12 December 2020

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease

1 reference

12 December 2020

10.2165/11584380-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21142270%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

17 January 2020

0 references

1 reference